Combined PD-1/PD-L1 and Tim-3/galectin-9 blockade could rescue mice from AML lethality [45], and this may be beneficial for preventing CD8+T-cell exhaustion in patients with hematological malignancies. Here, CD8A is linked to acute myeloid leukemia.